{"id":"W3032740647","doi":"10.1200/jco.2020.38.15_suppl.8500","title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Tolerability; Neutropenia; Adverse effect; Internal medicine; Dexamethasone; Multiple myeloma; Bortezomib; Febrile neutropenia; Gastroenterology; Pharmacology; Oncology; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009072573,0.0001665781,0.0007336828,0.0000606632,0.00004426875,0.000006722679,0.0003679671,0.000249948,0.00001159642],"category_scores_gemma":[0.001425611,0.0001002122,0.0001465853,0.0002028562,0.0001714223,0.00001466474,0.0001209475,0.0006642791,8.963243e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006591747,"about_ca_system_score_gemma":0.0005038403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003149562,"about_ca_topic_score_gemma":0.0008531472,"domain_scores_codex":[0.9972084,0.0004404497,0.001548485,0.0002738559,0.0003418538,0.00018699],"domain_scores_gemma":[0.9975371,0.0002273401,0.001534087,0.0002639928,0.0002568786,0.0001805987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02836226,0.07965887,0.8695741,0.0000378013,0.0003716255,0.0000881666,0.0008110602,0.0004287617,0.01114011,0.00001402926,0.0007543509,0.00875892],"study_design_scores_gemma":[0.2082429,0.1744004,0.5947683,0.0001197845,0.0001187019,0.00001011874,0.0006871894,0.000251688,0.007282862,0.000009344005,0.01382943,0.0002793043],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980499,0.00003762614,0.0001288527,0.0009009939,0.0002183139,0.0005448815,0.000005480507,0.000002398065,0.0001115384],"genre_scores_gemma":[0.9984455,0.00001994406,0.000595074,0.0007006366,0.0001701606,0.000009835943,0.000006422224,0.00001904111,0.00003341688],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2748058,"threshold_uncertainty_score":0.4086534,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05902830631515678,"score_gpt":0.363408366161987,"score_spread":0.3043800598468303,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}